Epigallocatechin-3-gallate-mediated cardioprotection by Akt/GSK-3β/caveolin signalling in H9c2 rat cardiomyoblasts

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Hsieh, Shih Ron ^a   Hsu, Chen Sen ^b   Lu, Chen Hua ^b   Chen, Wei Cheng ^c   Chiu, Chun Hwei ^b   Liou, Ying Ming ^b,d  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Caveolin; Cell cycle; EGCg; EGFP; H9c2; Oxidative stress

Indexed keywords

BETA ACTIN; CALCIUM; CAVEOLIN; CAVEOLIN 1; CAVEOLIN 3; ENHANCED GREEN FLUORESCENT PROTEIN; EPIGALLOCATECHIN GALLATE; GAP JUNCTION PROTEIN; HYDROGEN PEROXIDE; LAMININ RECEPTOR; MYOSIN; MYOSIN IX; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VIMENTIN; CATECHIN; CAV PROTEIN, RAT; DRUG DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL CYCLE ARREST; FLUORESCENCE SPECTROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; HEART MUSCLE ISCHEMIA; HEART PROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; RAT; ANIMAL; CELL LINE; CELL SURVIVAL; DRUG EFFECT; HEART MUSCLE CELL; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROFLUOROMETRY;

RATTUS;

ANIMALS; CATECHIN; CAVEOLIN 1; CELL LINE; CELL SURVIVAL; GLYCOGEN SYNTHASE KINASE 3; HYDROGEN PEROXIDE; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROMETRY, FLUORESCENCE;

EID: 84887741336     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-86     Document Type: Article

References (49)

1. Molecular targets of tea polyphenols in the cardiovascular system. Stangl V, Dreger H, Stangl K, Lorenz M, Cardiovasc Res 2007 73 348 358 10.1016/j.cardiores.2006.08.022 17020753 (Pubitemid 44937692)
2. Potential role of green tea catechins in various disease therapies: Progress and promise. Mak JC, Clin Exp Pharmacol Physiol 2012 39 265 273 10.1111/j.1440-1681.2012.05673.x 22229384
3. Green tea extract protects rats against myocardial infarction associated with left anterior descending coronary artery ligation. Shieh SR, Tsai DC, Chen JY, Tsai SW, Liou YM, Pflugers Arch 2009 458 631 642 10.1007/s00424-009-0655-1 19263074
4. Green tea extract given before regional myocardial ischemia-reperfusion in rats improves myocardial contractility by attenuating calcium overload. Liou YM, Hsieh SR, Wu TJ, Chen JY, Pflugers Arch 2010 460 1003 1014 10.1007/s00424-010-0881-6 20922441
5. Characteristics of catechin- and theaflavin-mediated cardioprotection. Dreger H, Lorenz M, Kehrer A, Baumann G, Stangl K, Stangl V, Exp Biol Med (Maywood) 2008 233 427 433 10.3181/0710-RM-292 18367631 (Pubitemid 351469298)
6. Identification of a PKC-dependent regulation of myocardial contraction by epicatechin-3-gallate. Li D, Yang C, Chen Y, Am J Physiol Heart Circ Physiol 2008 294 345 H353 17951366
7. Positive inotropic effects of epigallocatechin-3-gallate (EGCG) involve activation of Na§ssup§+§esup§/ H§ssup§+§esup§ and Na§ssup§+§esup§/ Ca§ssup§2+§esup§ exchangers. Lorenz M, Hellige N, Rieder P, Eur J Heart Fail 2008 10 439 445 10.1016/j.ejheart.2008.03.004 18406205
8. Protective effects of EGCg or GCg, a green tea catechin epimer, against postischemic myocardial dysfunction in guinea-pig hearts. Hirai M, Hotta Y, Ishikawa N, Wakida Y, Fukuzawa Y, Isobe F, Nakano A, Chiba T, Kawamura N, Life Sci 2007 80 1020 1032 10.1016/j.lfs.2006.11.032 17174345 (Pubitemid 46204721)
9. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M, Suzuki H, Knight RA, Latchman DS, Stephanou A, FASEB J 2004 18 1621 1623 15319365 (Pubitemid 39561653)
10. Lipid raft redox signaling: molecular mechanisms in health and disease. Jin S, Zhou F, Katirai F, Li PL, Antioxid Redox Signal 2011 15 1043 1083 10.1089/ars.2010.3619 21294649
11. Lipid raft in cardiac health and disease. Das M, Das DK, Curr Cardiol Rev 2009 5 105 111 10.2174/157340309788166660 20436850
12. Membrane microdomains and caveolae. Kurzchalia TV, Parton RG, Curr Opin Cell Biol 1999 11 424 431 10.1016/S0955-0674(99)80061-1 10449327 (Pubitemid 29396787)
13. The Caveolin genes: from cell biology to medicine. Williams TM, Lisanti MP, Ann Med 2004 36 584 595 10.1080/07853890410018899 15768830 (Pubitemid 40051435)
14. A ménage à trois made in heaven: G-protein-coupled receptors, lipids and TRP channels. Kukkonen JP, Cell Calcium 2011 50 9 26 10.1016/j.ceca.2011.04.005 21616532
15. Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. Head BP, Patel HH, Roth DM, Murray F, Swaney JS, Niesman IR, Farquhar MG, Insel PA, J Biol Chem 2006 281 26391 26399 10.1074/jbc.M602577200 16818493 (Pubitemid 44401847)
16. Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase implications for vascular disease. Everson WV, Smart EJ, Trends Cardiovasc Med 2001 11 246 250 10.1016/S1050-1738(01)00119-0 11673056 (Pubitemid 32982916)
17. Immunolocalization of caveolin-1 and caveolin-3 in monkey skeletal, cardiac and uterine smooth muscles. Hagiwara Y, Nishina Y, Yorifuji H, Kikuchi T, Cell Struct Funct 2002 27 375 382 10.1247/csf.27.375 12502892 (Pubitemid 36149992)
18. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. Patel HH, Tsutsumi YM, Head BP, Niesman IR, Jennings M, Horikawa Y, Huang D, Moreno AL, Patel PM, Insel PA, Roth DM, FASEB J 2007 21 1565 1574 10.1096/fj.06-7719com 17272740 (Pubitemid 46684858)
19. Caveolin-3 expression and caveolae are required for isoflurane induced cardiac protection from hypoxia and ischemia/reperfusion injury. Horikawa YT, Patel HH, Tsutsumi YM, Jennings MM, Kidd MW, Hagiwara Y, Ishikawa Y, Insel PA, Roth DM, J Mol Cell Cardiol 2008 44 123 130 10.1016/j.yjmcc.2007.10.003 18054955
20. The anti-cancer effects of (-)-epigalocathine-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. Hsu YC, Liou YM, J Cell Physiol 2011 226 2721 2730 10.1002/jcp.22623 21792929
21. A new generation of Ca§ssup§2+§esup§ indicators with greatly improved fluorescence properties. Grynkiewicz G, Poenie M, Tsien RY, J Biol Chem 1985 260 3440 3450 3838314 (Pubitemid 15114340)
22. Effects of genistein on β-catenin signaling and subcellular distribution of actin-binding proteins in human umbilical CD105-positive stromal cells. Shieh DB, Li RY, Liao JM, Chen GD, Liou YM, J Cell Physiol 2010 223 423 434 20082305
23. Differential role of actin-binding proteins in controlling the adipogenic differentiation of human CD105-positive Wharton's jelly cells. Peng KW, Liou YM, Biochim Biophys Acta 1820 2012 469 481
24. Differential effects of a green tea-derived polyphenol (-)-epigallocatechin-3-gallate on the acidosis-induced decrease in the Ca§ssup§2+§esup§ sensitivity of cardiac and skeletal muscle. Liou YM, Kuo SC, Hsieh SR, Pflugers Arch 2008 456 787 800 10.1007/s00424-008- 0456-y 18231806
25. Matrix metalloproteinase-7 affects Connexin-43 levels, electrical conduction, and survival after myocardial infarction. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matrisian LM, Spinale FG, Circulation 2006 113 2919 2928 10.1161/CIRCULATIONAHA.106.612960 16769909 (Pubitemid 44297233)
26. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, Duplaà C, Jaspard-Vinassa B, Cardiovasc Res 2011 90 49 56 10.1093/cvr/cvr002 21233250
27. Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload. Omar MA, Wang L, Clanachan AS, Cardiovasc Res 2010 86 478 486 10.1093/cvr/cvp421 20053658
28. Role of glycogen synthase kinase-3beta in cardioprotection. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ, Circ Res 2009 104 1240 1252 10.1161/CIRCRESAHA.109.197996 19498210
29. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Takahashi-Yanaga F, Sasaguri T, Cell Signal 2008 20 581 589 10.1016/j.cellsig. 2007.10.018 18023328 (Pubitemid 351241128)
30. A receptor for green tea polyphenol EGCG. Tachibana H, Koga K, Fujimura Y, Yamada K, Nat Struct Mol Biol 2004 11 380 381 10.1038/nsmb743 15024383 (Pubitemid 38436804)
31. Cytoskeleton-membrane interactions in membrane raft structure. Chichili G, Rodgers W, Cell Mol Life Sci 2009 66 2319 2328 10.1007/s00018-009-0022-6 19370312
32. Lipid raft microdomains and neurotransmitter signaling. Allen JA, Halverson-Tamboli RA, Rasenick MM, Nat Rev Neurosci 2007 8 128 140 10.1038/nrn2059 17195035 (Pubitemid 46146951)
33. Myocardial AKT: the omnipresent nexus. Sussman MA, Völkers M, Fischer K, Bailey B, Cottage CT, Din S, Gude N, Avitabile D, Alvarez R, Sundararaman B, Quijada P, Mason M, Konstandin MH, Malhowski A, Cheng Z, Khan M, McGregor M, Physiol Rev 2011 91 1023 1070 10.1152/physrev.00024.2010 21742795
34. The cardiac mitochondrion: nexus of stress. Baines CP, Annu Rev Physiol 2010 72 61 80 10.1146/annurev-physiol-021909-135929 20148667
35. Cell death in the pathogenesis of heart disease: mechanisms and significance. Whelan RS, Kaplinskiy V, Kitsis RN, Annu Rev Physiol 2010 72 19 44 10.1146/annurev.physiol.010908.163111 20148665
36. Proteomics study of oxidative stress and Src kinase inhibition in H9c2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment. Chou HC, Chen YW, Lee TR, Wu FS, Chan HT, Lyu PC, Timms JF, Chan HL, Free Radic Biol Med 2010 49 96 108 10.1016/j.freeradbiomed.2010.04.001 20385227
37. Epigallocatechin gallate protects H9c2 cardiomyoblasts against hydrogen dioxides-induced apoptosis and telomere attrition. Sheng R, Gu ZL, Xie ML, Zhou WX, Guo CY, Eur J Pharmacol 2010 641 199 206 10.1016/j.ejphar.2010.05.054 20553906
38. Phospho-regulation of Beta-catenin adhesion and signaling functions. Daugherty RL, Gottardi CJ, Physiology 2007 22 303 309 10.1152/physiol.00020.2007 17928543
39. Lysosomal trafficking of beta-catenin induced by the tea polyphenol epigallocatechin-3-gallate. Dashwood WM, Carter O, Al-Fageeh M, Li Q, Dashwood RH, Mutat Res 2005 591 161 172 10.1016/j.mrfmmm.2005.03.029 16054165 (Pubitemid 41654846)
40. Lipid raft redox signaling platforms in endothelial dysfunction. Li PL, Zhang Y, Yi F, Antioxid Redox Signal 2007 9 1457 1470 10.1089/ars.2007.1667 17661535 (Pubitemid 47255026)
41. Lipid raft clustering and redox signaling platform formation in coronary arterial endothelial cells. Zhang AY, Yi F, Zhang G, Gulbins E, Li PL, Hypertension 2006 47 74 80 10.1161/10.1161/01.HYP.0000196727.53300.62 16344372 (Pubitemid 43177818)
42. Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Tsutsumi YM, Horikawa YT, Jennings MM, Kidd MW, Niesman IR, Yokoyama U, Head BP, Hagiwara Y, Ishikawa Y, Miyanohara A, Patel PM, Insel PA, Patel HH, Roth DM, Circulation 2008 118 1979 1988 10.1161/CIRCULATIONAHA.108.788331 18936328
43. Behavior of caveolae and caveolin-3 during the development of myocyte hypertrophy. Kikuchi T, Oka N, Koga A, Miyazaki H, Ohmura H, Imaizumi T, J Cardiovasc Pharmacol 2005 45 204 210 10.1097/01.fjc.0000152029.53997.57 15725944 (Pubitemid 40328141)
44. Mechanical unloading increases caveolin expression in the failing human heart. Uray IP, Connelly JH, Frazier OH, Taegtmeyer H, Davies PJA, Cardiovasc Res 2003 59 57 66 10.1016/S0008-6363(03)00352-3 12829176 (Pubitemid 36780949)
45. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Jasmin JF, Mercier I, Hnasko R, Cheung MW, Tanowitz HB, Dupuis J, Lisanti MP, Cardiovasc Res 2004 63 747 755 10.1016/j.cardiores.2004.05.018 15306231 (Pubitemid 39078689)
46. Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy. Piech A, Massart PE, Dessy C, Feron O, Havaux X, Morel N, Vanoverschelde JL, Donckier J, Balligand JL, Am J Physiol Heart Circ Physiol 2002 282 219 H231 11748066
47. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Hare JM, Lofthouse RA, Juang GJ, Colman L, Ricker KM, Kim B, Senzaki H, Cao S, Tunin RS, Kass DA, Circ Res 2000 86 1085 1092 10.1161/01.RES.86.10.1085 10827139 (Pubitemid 30367868)
48. Chronic myocardial hypoxia increases nitric oxide synthase and decreases caveolin-3. Shi Y, Pritchard KA Jr, Holman P, Rafiee P, Griffith OW, Kalyanaraman B, Baker JE, Free Radic Biol Med 2000 29 695 703 10.1016/S0891-5849(00)00364-6 11053770
49. Altered cholesterol localization and caveolin expression during the evolution of acute renal failure. Zager RA, Johnson A, Hanson S, Dela Rosa V, Kidney Int 2002 61 1674 1683 10.1046/j.1523-1755.2002.00316.x 11967017 (Pubitemid 34437921)